The DOI matches its Crossref record; 117 of the 119 references it cites were found in a registry or an index.
Statins as Anticancer Agents in the Era of Precision Medicine
Abstract
Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate metabolic pathway. Multiple lines of evidence indicate that certain cancers depend on the mevalonate pathway for growth and survival, and, therefore, are vulnerable to statin therapy. However, these immediately available, well-tolerated, and inexpensive drugs have yet to be successfully repurposed and integrated into cancer patient care. In this review, we highlight recent advances and outline important considerations for advancing statins to clinical trials in oncology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mevalonate pathway byproducts, farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), determine the KRAS protein prenylation which in turn determines the KRAS anchoring to the cell membrane, facilitating the KRAS-mediated cell signaling (Longo et al., 2020).”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Longo et al., 2020
Citations
Cites
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., et al. (2017) · Nature · doi:10.1038/nature23007 · Cited by 2,011 · cited 1×
“, E-cadherin) are highly sensitive to statin treatment (24, 34, 35).”
BackgroundCholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment
Ma, X., Bi, E., Lu, Y., Su, P., Huang, C., Liu, L., Wang, Q., Yang, M., Kalady, M. F., Qian, J., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.04.002 · Cited by 1,033 · cited 2×
“Importantly, reducing cholesterol levels in the tumor microenvironment or in CD8þ T cells restores T-cell antitumor activity (101).”
BackgroundStatin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030 · cited 3×
“, p53mut, t(4;14) translocation) • Impaired SREBP-mediated feedback response Examples of features: Statin Statin”
BackgroundMutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
Statins and the Risk of Colorectal Cancer
Poynter, J. N., Gruber, S. B., Higgins, P. D. R., Almog, R., Bonner, J. D., Rennert, H. S., Low, M., Greenson, J. K., & Rennert, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043792 · Cited by 816
Statin Toxicity: Mechanistic Insights and Clinical Implications
Ward, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.312782 · Cited by 757 · cited 2×
“Metabolism (104) Solubility (104) Atorvastatin (Lipitor) N/A 10–20 40–80 CYP3A4 Lipophilic Rosuvastatin (Crestor) N/A 5–10 20–40 Non-CYP450 (limited CYP2C9/8) Hydrophilic Simvastatin (Zocor) 10 20–40 N/A CYP3A4 Lipophilic Pravastatin (Pravachol) 10–20 40–80 N/A Non-CYP450 Hydrophilic Lovastatin (Mevacor) 20 40–80 N/A…”
Statin Use and Reduced Cancer-Related Mortality
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1214827 · Cited by 720
The interplay between cell signalling and the mevalonate pathway in cancer
Mullen, P. J., Yu, R., Longo, J., Archer, M. C., & Penn, L. Z. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.76 · Cited by 699 · cited 2×
“EGFR inhibitors Given the interplay between themevalonate pathway and oncogenic signal transduction (1), numerous studies have evaluated the combination of a statinwith various agents that target cell signaling (Table 3).”
BackgroundSelf-citationZhuang, L., Kim, J., Adam, R. M., Solomon, K. R., & Freeman, M. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200519935 · Cited by 567 · cited 2×
“It is important to note that, unlike in humans, statin treatment does not reduce serum cholesterol levels in mice (20, 29).”
Background
Cited by
Lipid metabolism in cancer: New perspectives and emerging mechanisms
Broadfield, L. A., Pane, A. A., Talebi, A., Swinnen, J. V., & Fendt, S.-M. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.04.013 · Cited by 758
Statins: a repurposed drug to fight cancer
Jiang, W., Hu, J.-W., He, X.-R., Jin, W.-L., & He, X.-Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02041-2 · Cited by 417
“However, in the era of precision medicine, further investigation into drug combination strategies will remain an important area of research [296].”
BackgroundThe Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
Cunningham, R., & Hansen, C. G. (2022) · Clinical Science · doi:10.1042/cs20201474 · Cited by 326
Emerging mechanisms and targeted therapy of ferroptosis in cancer
Wang, H., Cheng, Y., Mao, C., Liu, S., Xiao, D., Huang, J., & Tao, Y. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.03.022 · Cited by 312
Acetyl-CoA metabolism in cancer
Guertin, D. A., & Wellen, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00543-5 · Cited by 303
Metadata
- Authors
- Longo, J., van Leeuwen, J. E., Elbaz, M., Branchard, E., & Penn, L. Z.
- Affiliations
- University Health Network (CA)
- Corresponding author
- Penn, Linda Z.
- Venue
- Clinical Cancer Research
- Published
- 2020-11-13
- Volume
- 26
- Issue
- 22
- Pages
- 5791-5800
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W3083506235
- Cited by
- 196
- References
- 119
- Citations by year
- 2026: 17 · 2025: 37 · 2024: 41 · 2023: 30 · 2022: 41 · 2021: 30
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (FRN: 142263)
- Terry Fox Research Institute (PPG-1064)
- Canadian Cancer Society (#706394)
- Office of the Assistant Secretary of Defense for Health Affairs (W81XWH-16-1-0068)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- statins, anticancer agents, drug repurposing, HMG-CoA reductase inhibition, mevalonate pathway, cancer metabolism, precision medicine
- MeSH terms
- Antineoplastic Agents, Humans, Mevalonic Acid, Neoplasms, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Metabolic Networks and Pathways, Precision Medicine, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statins as Anticancer Agents in the Era of Precision Medicine. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-1967
- The paper
- Longo, J., van Leeuwen, J. E., Elbaz, M., Branchard, E., & Penn, L. Z. (2020). Statins as Anticancer Agents in the Era of Precision Medicine. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-1967
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.